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Abstract
Background: This systematic review gives an overview of guidelines and original publications as well as the
evidence on which the currently proposed indication criteria are based. Until now such a state-of-the-science
overview was lacking.
Methods: Websites of orthopaedic and arthritis organizations (English/Dutch language) were independently
searched by two authors for THA/TKA guidelines for OA. Furthermore, a systematic search strategy in several
databases through August 2014 was performed. Quality of the guidelines was assessed with the AGREE II
instrument, which consists of 6 domains (maximum summed score of 6 indicating high quality). Also, the level of
evidence of all included studies was assessed.
Results: We found 6 guidelines and 18 papers, out of 3065 references. The quality of the guidelines summed
across 6 domains ranged from 0.46 to 4.78. In total, 12 THA, 10 TKA and 2 THA/TKA indication sets were found.
Four studies stated that no evidence-based indication criteria are available. Indication criteria concerning THA/TKA
consisted of the following domains: pain (in respectively 11 and 10 sets), function (12 and 7 sets), radiological
changes (10 and 9 sets), failed conservative therapy (8 and 4 sets) and other indications (6 and 7 sets). Specific
cut-off values or ranges were often not stated and the level of evidence was low.
Conclusion: The indication criteria for THA/TKA are based on limited evidence. Empirical research is needed,
especially regarding domain specific cut-off values or ranges at which the best postoperative outcomes are
achieved for patients, taking into account the limited lifespan of a prosthesis.
Background
Total hip and knee arthroplasty (THA/TKA) have been
widely performed since the 1970s. In 2009 over a million
of THA and TKA were carried out in the United States
[1]. Osteoarthritis (OA) is the main clinical indication
for which these procedures are performed [2]. Due to
the ageing society as well as the obesity epidemic, the
prevalence of OA is increasing [3]. As a result the
procedure rates of THA and TKA are expected to
rise, some estimates even indicate a quadruple de-
mand by 2030 [4, 5].
The rise in THA/TKA surgery has important implica-
tions for health care costs as well as capacity. As such, it
is of utmost importance that patients are carefully se-
lected, and that these procedures are optimally timed to
achieve the best possible patient outcomes and that revi-
sion surgery is prevented thereby reducing costs and
worse outcomes. However, large heterogeneity exists in
the patients disease severity at the time of surgery [6, 7].
This can partly be explained by the patient’s own wishes,
with some patients preferring a THA/TKA to continue
an active lifestyle whereas others request surgery to be
able to perform daily living activities. In addition, the
attitude of the surgeon towards arthroplasty plays an
important role since surgeons with a positive attitude
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towards this procedure will have higher surgery rates.
This may explain why studies on appropriateness criteria
for THA/TKA showed that in approximately 20-45 % of
patients appropriateness of arthroplasty was considered
uncertain [8–11]. All of these may explain to some ex-
tent why a substantial proportion of the patients is un-
satisfied after THA and TKA (10-30 %), indicating that
outcomes are less than expected and/or that expecta-
tions were too high [12]. Therefore, evidence-based indi-
cation criteria for THA/TKA to guide decision making
are warranted to improve optimal timing and patient se-
lection, which is internationally acknowledged [13–18].
Guidelines concerning THA and TKA indications
have been published and several studies regarding the
appropriateness of THA and TKA have been conducted
[3, 13, 19–21]. However, an overview of the evidence
on which the proposed indication criteria are based is
lacking, to guide decision making on timing of THA
and TKA. In the present study the available guidelines
and their indication sets for primary THA and TKA
will be reviewed. In addition, we assess the quality of
these guidelines and the evidence on which the indica-
tion sets are based. In the second part a systematic
search is conducted of scientific publications containing
proposed indication sets for primary THA and TKA in
OA or expert opinion.
Methods
Search strategy
Websites of orthopaedic and arthritis organizations
(English or Dutch websites) were independently searched
by two authors for guidelines concerning primary THA/
TKA for OA. When these websites cross-linked to guide-
lines from other organizations these were also included.
All available guidelines published since January 1, 2000
were included. A librarian-assisted search strategy was
performed on August 3 2014 to retrieve additional publi-
cations on THA/TKA indications. The following data-
bases were searched: Pubmed, MEDLINE, Embase, Web
of Science, the COCHRANE Librabry, CENTRAL and
CINAHL. Searches were limited to English, Dutch and
German language papers published since January 1, 2000
(see Additional file 1).
Selection of publications
First titles and abstracts were independently screened by
two authors (MG/SH).The full-text articles were
reviewed by MG and were included when the following
criteria were met: studies reporting about indication cri-
teria and/or appropriateness of decision tools for pri-
mary THA/TKA in OA. Papers involving guidelines on
unicompartimental replacements, resurfacing or revision
of THA/TKA were excluded if no separate indications
for primary THA/TKA were provided. Also papers on
prioritizing tools to reduce waiting times were excluded
unless these reported on the appropriateness of surgery
as all of these patients on the waiting list already have
an indication and variables determining priority are not
necessarily the same as variables determining an indica-
tion for surgery.
The included papers where checked by a second au-
thor (SH). If disagreement existed the authors tried to
reach consensus, when necessary a third author had the
decisive vote (PM). When a guideline was also published
as a scientific paper, only the guideline was included.
Data extraction
The following information was extracted from the guide-
lines by MG: orthopaedic or arthritis organization, publi-
cation date, indication criteria and the level of evidence
on which indication criteria were based (see below). We
extracted the following information from the publica-
tions: first author, publication date, country where the
indication criteria were developed, the organization(s)
that initiated the development of the criteria, study type,
indication criteria and the level of evidence on which in-
dication criteria were based. The level of evidence was
scored according to the following the criteria [3]:
➢ Ia evidence from meta-analysis of randomized con-
trolled trials
➢ Ib evidence from at least one randomized
controlled trial
➢ IIa evidence from at least one controlled study
without randomization
➢ IIb evidence from at least one well-designed quasi-
experimental study
➢ III evidence from at least one non-experimental
descriptive study, such as comparative studies,
correlation studies, and case-control studies
➢ IV evidence from expert committee reports or
opinions or clinical experience of respected
authorities or both
Data extraction and level of evidence score was
checked by SH.
Quality of the guidelines
Guideline quality was assessed with the validated
AGREE-II instrument (Appraisal of Guidelines for
Research and Evaluation, Dutch version) [22]. This in-
strument evaluates the process of practice guideline de-
velopment and the quality of reporting. Two authors
independently scored the guidelines according to the
AGREE-II protocol (MG/SH). When large differences
existed the authors tried to reach consensus, when ne-
cessary a third author had the decisive vote (PM).
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The AGREE-II consists of six quality domains: 1)
scope and purpose, 2) stakeholder involvement, 3) rigour
of development, 4) clarity of presentation, 5) applicabil-
ity and 6) editorial independence. Each domain entails
several questions which are rated from 1 (lowest score)
to 7 (highest score), with 1 rated for items with no clear
discussion or no specific information, 7 for exceptional
reporting quality, 2–6 for items not fully meeting the
AGREE-II criteria. Scaled domain scores were calculated
using the following formula:
Obtained score ‐ Minimum possible scoreð Þ
Maximum possible score ‐ Minimum possible scoreð Þ
The scores will always lie between 0 and 1, with scores
closer to 1 indicating higher quality. The scaled domain
scores from the two authors were averaged to obtain
one quality score for each domain. We summed the
scaled domain scores across the 6 domains to obtain 1
overall guideline score. The maximum summed score
was thus 6, indicating high quality.
Results
Across guidelines and studies, 12 THA, 10 TKA and 2
THA/TKA indication sets were found.
Guidelines
We found six guidelines concerning THA, of which three
specific OA guidelines (EULAR [20], NICE [23] and
OARSI [3]). In addition, five guidelines concerning TKA
were found, of which four OA specific guidelines (BOA
[24], EULAR [19], NICE [23] and OARSI [3]) (Table 1).
Indication criteria concerning THA and TKA
Most indication criteria consisted of the following three
domains: pain, function and radiological changes, with
the prerequisite that pain could not be controlled by
conservative therapy (Table 1). Specific cut-off values or
ranges for pain and function were not reported. For
radiological changes only the BOA TKA guideline re-
ported a cut-off value (Kellgren Lawrence grade ≥ III).
The evidence on which the indication criteria were
based was rated as low quality evidence (level IV).
Quality of the guidelines
The quality of the guidelines differed considerably be-
tween the AGREE-II domains and the guidelines (Fig. 1).
The ranges of the scaled domain scores were: scope and
purpose 0.06-0.81, stakeholder involvement 0.19-0.75,
rigour of development 0.03-0.88, clarity of presentation
0.33-0.89, applicability 0-0.50, editorial independence 0-
0.96. Low scores were frequently attained in the editorial
independence domain due to no clear statement on the
influence of the funding body and competing interests.
In addition, low scores were often attained in the applic-
ability domain, due to no clear statements on monitor-
ing/auditing criteria of the guideline or facilitators and
barriers to the application of the guideline. The OARSI
and NOV guidelines attained the highest overall scores,
4.78 and 4.46 respectively. This is explained because
both guidelines were developed according to the
AGREE-II. The lowest scores were attained by the NZ
guidelines, THA (0.84) and TKA (0.46). These guidelines
primarily consisted of a, from the BOA guidelines de-
rived, summary of statements concerning THA/TKA
but limited information on the required 6 domains.
Although the process of guideline development and
quality of reporting differed considerably between the
guidelines, the given indication criteria for primary THA
and TKA are similar across guidelines (pain, function,
radiological changes). Hence, it seems that guideline
quality did not influence the main domains included in
the indication sets.
Publications
Our literature search yielded 3065 references (Fig. 2), the
full-text of 88 papers was assessed on eligibility. Of these
70 were excluded mainly because no indication criteria for
THA/TKA in OA patients were reported. Finally, 18
papers were included (12 reviews/6 original studies).
Reviews
Of the included 12 reviews, only 2 were systematic re-
views (Table 2) [25, 26]. Furthermore, only 2 reviews fo-
cussed on indications for THA/TKA as their main topic
[27, 28]. In addition, 1 review investigated the indica-
tions for THA/TKA referral [29]. Other topics on which
the reviews focussed were management of THA/TKA
[30–32], effectiveness of THA/TKA [26] and state of the
art overviews of THA/TKA [14, 33, 34].
Pain not responsive to conservative treatment, in pa-
tients who have functional limitations and radiographic
evidence of joint degeneration was most often reported
as THA/TKA indication (Table 2). No specific cut-off
values were mentioned. It was often not stated if devia-
tions in all these domains should be apparent, or which
combinations should be apparent to indicate THA or
TKA. Furthermore, the evidence behind all these indica-
tion criteria was very low (level IV). In 3 of the reviews
the experts explicitly stated that no appropriate indica-
tion sets are available for performing THA/TKA.
Original publications
Three original publications reported on TKA [8, 9, 35]
and 3 on THA [10].
Yamabe et al. [35] considered severe cartilage defects
as an optimal indication for TKA. In their discussion
section they also included pain but no referral was made
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Table 1 Guidelines and their indication criteria concerning total hip arthroplasty and total knee arthroplasty
Guideline Year of
publication
OA specific Evidence Indication criteria







2013 Yes Level IV Moderate or severe
pain
KL > III in at least one
of the knee joints
compartments
Yes Patients outside these criteria may still be
considered for surgery but a second opinion/
recorded case discussion is advised. Cases
focus on patients without pain (primary
indication) but who present with: functional
disability in the presence of end stage cartilage
disease. Progressive deformity of the knee
(varus/valgus) with functional disability.
Eular [19] 2003 Yes Level IV Refractory pain Disability Radiological evidence
of knee OA
NZ [40] ? No, but based on
BOA guidelines
which is OA specific
Level IV Severe pain Disability Radiological changes Yes Occasionally there may be an indication to
replace a knee because of progressive deformity
and/or instability, and pain may not necessarily
be the most significant factor. Where
comorbidities exist risk benefit considerations











Yes Compromised quality of life
Eular [20] 2005 Yes Level IV Refractory pain Disability Radiological evidence
of hip OA
NOV [42] 2010 No Level IV Pain Function loss Radiological changes Yes Younger age and obesity are relative
contraindications. Delay of surgery in high
age is not advisable in view of reduced
functional outcome and increased mortality.
In addition when progressive loss of function
(with or without contractures) predominates
over pain, surgery should not be delayed in
view of reduced postoperative functional outcome.
NZ [43] ? No Level IV Significant pain Disability Radiological changes Yes
Joint






NICE [23] 2014 Yes Level IV Pain Stiffness and
reduced function
Yes Substantial impact on quality of life















to any evidence or the way these indications were
established.
The other 5 included original studies investigated deci-
sion tools to assess the appropriateness of TKA (n = 2)
[8, 9] or THA (n = 3) [10, 11, 36] in OA patients.
TKA appropriateness
Two studies evaluated algorithms to assess TKA appro-
priateness [8, 9]. The Escobar algorithm was established
using the RAND/UCLA appropriateness method, in
which expert opinion is combined with available scien-
tific evidence [37]. The following variables where taken
into account in different combinations: symptomatology,
radiology, age, mobility and stability, previous surgical
management and localization. Symptomatology and
radiology were the largest contributors in explaining the
variability of appropriateness in their model. Table 3 de-
picts various scenarios in which TKA was considered in-
appropriate, uncertain or appropriate [9]. However,
appropriateness was rated uncertain in a high percentage
of scenarios (24.5 %). Another study showed that patients
with their TKA rated as appropriate were more likely to
achieve better health-related quality of life than patients
for whom the TKA was rated as inappropriate [38].
Riddle et al. modified the Escobar algorithm to attain a
decision tool for US patients [8]. They used the Kellgren
Lawrence score rather than the Ahlbäck classification
and quantified symptomatology using the Western On-
tario and McMaster osteoarthritis index (WOMAC). In
21.7 % of patients appropriateness of TKA was rated as
uncertain.
THA appropriateness
Quintana et al. developed three THA appropriateness
algorithms in OA patients [10, 11, 36]. Two were estab-
lished using the RAND/UCLA appropriateness method.
These algorithms took the following variables into ac-
count: age, surgical risk, previous nonsurgical treat-
ments, pain and functional limitation. Table 4 depicts
various scenarios in which THA was considered in-
appropriate, uncertain or appropriate [10]. In both algo-
rithms, appropriateness was rated uncertain in a large
part of patients, 46.2 % and 32.4 %. Both algorithms
were validated in a population of OA patients scheduled
for THA [10, 11]. Patients rated as appropriate THA
candidates had better outcomes at 3 months on the
WOMAC stiffness and functional limitation domains
compared to inappropriate candidates.
The other algorithm was based on the WOMAC as
they wanted to develop a tool based on a disease specific
instrument rather than on expert opinion [36]. Surgical
risk, pre-intervention pain and functional limitations
were found to significantly predict changes in the
WOMAC pain domain 6 months after THA and pre-
intervention functional limitations predicted changes in
the functional limitation domain [36]. In addition, by
means of a classification and regression tree analysis a
summary tree was constructed. THA was rated as ap-
propriate when pain was qualified as severe (according
to the pain and limitation short scales), when WOMAC
pain pre-intervention score was >60 or when WOMAC
functional limitation pre-intervention was >60 with pain
pre-intervention >40. Surgical risk was not included in
the decision tree. However, the authors stated that one
should be aware that higher surgical risk often results in












































































Fig. 1 AGREE II guideline quality scores. Panel (a) AGREE II quality
scores of the guidelines concerning hip replacement. Panel (b) AGREE II
quality scores of the guidelines concerning knee replacement. Panel (c)
AGREE II quality scores of the guidelines concerning joint replacement
in osteoarthritis. Domain 1: scope and purpose, domain 2: stakeholder
involvement, domain 3: rigour of development, domain 4: clarity of
presentation, domain 5: applicability, domain 6: editorial independence
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always be performed before considering THA. Again this
decision tool was validated in a THA cohort. They
assessed sensitivity and specificity of being classified as
appropriate compared with the appropriateness based
on the minimal clinical important difference values (gain
in WOMAC 6 months after THA, pain domain ≥30,
function domain ≥25). A sensitivity of 95.0 % and a spe-
cificity of 41.0 % were found, suggesting that it seems
difficult to identify the non-appropriate cases.
Discussion
In this systematic review we examined the quality and
evidence base of existing indication criteria and guide-
lines for primary THA and TKA in OA patients. Across
guidelines and publications we found, 12 THA, 10 TKA
and 2 THA/TKA indication sets. Only 6 guidelines in-
cluded indication criteria for THA/TKA with differing
quality. Overall quality of the guidelines summed across
the 6 domains ranged from 0.46 to 4.78. Low scores
were frequently attained in the editorial independence
domain and the applicability domain. High scores were
often attained in the clarity of presentation domain. In
the additional 12 reviews and 6 original publications
most indication criteria included the following three
domains: pain, function and radiological changes. Fre-
quently a prerequisite was that conservative treatment
had been insufficient in controlling pain. However, do-
main specific cut-off values or ranges were mostly not
reported. Also, it was often not stated if pain, functional
disability and radiological changes should all exist, or
which combinations of domain-specific deviations
should be apparent to indicate THA or TKA. The level
of evidence was low (level IV).
We were not able to discriminate between high and
poor quality guidelines as the AGREE-II has not given a
set of rules to define a high quality guideline. Given the
low scores in the applicability and the editorial inde-
pendence domains, we advise guideline developers to
pay more attention in reporting these issues. A
limitation of the current study may be that the scoring
of guidelines according to the AGREE-II is not com-
pletely objective, even though the manual clearly articu-
lates how each item should be scored including the
criteria and considerations for each item. However, the
weighting of criteria and considerations in the overall
scoring of the item is not mentioned, which could intro-
duce inter-observer variability. To cope with this, the
AGREE-II proposes to use more than one observer,
which is why the guidelines were scored independently
by two investigators and compared to reach consensus
(with or without a decisive vote of a third investigator).
As such, we tried to minimalize subjectivity.
Another limitation of this study is that we restricted
our search strategy to English, Dutch and German lan-
guage papers. In addition, our website search of ortho-
paedic and arthritis organizations was restricted to
English and Dutch websites. Therefore we may have
missed part of the existing literature on indication cri-
teria for THA/TKA.
Irrespective of the quality of individual guidelines, the
same domains concerning THA/TKA indications were
reported across most guidelines. Based on the design of
included studies, the highest level of evidence was re-
ported by the OARSI and EULAR guidelines (only non-
experimental studies, level III evidence). The evidence
on which indication sets were based came from studies
investigating the effectiveness and safety of THA/TKA,
but these studies did not specifically address THA/TKA
indication sets. Therefore the evidence from these
guidelines was rated as level IV evidence, so that the
evidence on which indication criteria are based, is
low quality evidence.
Looking at other literature, most of the reviews also
did not specifically focus on THA/TKA indications and
none of the systematic reviews did. Moreover, in 2 of 3
reviews with THA/TKA indication as the main topic it
was concluded that no conclusive evidence on THA/
TKA indications are currently available. Furthermore,
Fig. 2 Flow diagram
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Table 2 Reviews on indication criteria concerning total hip arthroplasty and total knee arthroplasty
Author Year of
publication
Study group region Systematic
review
Evidence Indication criteria






Hanssen [34] 2000 USA No Level IV As the indications continue
to expand, the decision to
proceed with total knee
arthroplasty in young,



































2005 Canada Yes Level IV Pain Functional ability
Schneppenheim
[28]
2001 Germany No Level IV Debilitating
pain
Severe restrictions on
the activities of the













Lane [33] 2007 USA No Level IV Substantial functional
impairment
Chronic discomfort
Levine [31] 2013 USA No Level IV Pain refractory
to nonsurgical
management
Functional impairment Radiographic findings (joint
space narrowing, bone
sclerosis, bone cysts femoral/
acetabular osteophytes
Yes Physical exam findings
(groin pain and decreased
internal rotation), ruled out
causes of referred pain
including spine problems
and bursitis























Table 2 Reviews on indication criteria concerning total hip arthroplasty and total knee arthroplasty (Continued)
conservative
therapy
to perform certain activities
that are deemed important
to the patient, and major
lifestyle changes













Yes Level III The criteria for when to
perform such surgery
are not clear.
Dowsey [27] 2014 Australia No Level III Selection of suitable
candidates for TJA is
critical but appropriate
criteria are not clearly
defined.
Mandl [29] 2013 USA No Level IV There are no definitive
recommendations for
deciding which patients
should be referred for TJA.















few original papers investigating THA/TKA indications
were found, which may be partly due to the employed
language restrictions, possibly resulting in language bias.
Four of five original studies came from the same group
and four were based on the RAND/UCLA method [8–11].
Although this is a respected approach, the limitation is
that the indication set is mainly based on expert opinion if
little research is available. Thus, even with an optimal
composition of experts in the panel, the level of evidence
will still be low. This is currently the case for THA/TKA
indication sets. In addition, within the proposed THA/
TKA decision tools, the appropriateness of surgery was
rated as uncertain in many patients. This makes these de-
cision tools difficult to use in daily practice, as patients
Table 4 Different scenarios in which THA is deemed appropriate, uncertain or inappropriate according to Quintana et al. [10]
Pain Non-surgical procedure Functional limitation Surgical risk Age Total hip arthroplasty
Severe Correctly Severe Appropriate
Severe Correctly Minor or moderate Appropriate
Severe Not done or not done correctly Severe Appropriate
Mild or moderate Correctly Severe Low Appropriate
Mild Minor Inappropriate
Mild Moderate High Inappropriate
Mild Moderate Low Inappropriate
Moderate or severe Not done or not done correctly <50 years Inappropriate
Moderate or severe Not done or not done Correctly Minor >50 years Inappropriate
Mild or moderate Not done or not done correctly Severe Low Uncertain
Mild or moderate Not done or not done correctly Severe High Uncertain
Mild or moderate Correctly Severe High Uncertain
Severe Not done or not done correctly Minor or moderate Uncertain
Moderate Correctly Minor or moderate High Uncertain
Moderate Correctly Minor or moderate Low Uncertain
Moderate Not done or not done correctly Moderate >50 Uncertain
Mild Correctly Moderate Low Uncertain
Table 3 Different scenarios in which TKA is deemed appropriate, uncertain or inappropriate according to Escobar et al. [9]
Symptoms Radiology Age Mobility Localisation Total knee arthroplasty
Slight or moderate Ahlbäck I-III Inappropriate
Slight Ahlbäck IV-V Inappropriate
Moderate Ahlbäck IV-V <55 Inappropriate
Moderate Ahlbäck IV-V ≥55 Uni Inappropriate
Moderate Ahlbäck IV-V ≥55 Bi-tri Appropriate
Intense-severe Ahlbäck I-III <55 Uni-bi Inappropriate
Intense-severe Ahlbäck I-III <55 Tri Uncertain
Intense-severe Ahlbäck I ≥55 Normal Inappropriate
Intense-severe Ahlbäck II-III ≥55 Normal Uncertain
Intense-severe Ahlbäck I 55-65 Limited Uncertain
Intense Ahlbäck I >65 Limited Uncertain
Severe Ahlbäck I >65 Limited Appropriate
Intense-severe Ahlbäck II-III ≥55 Limited Appropriate
Intense-severe Ahlbäck IV-V <55 Uni Uncertain
Intense-severe Ahlbäck IV-V <55 Bi-tri Appropriate
Intense-severe Ahlbäck IV-V ≥55 Appropriate
Legend: uni: unicompartmental excluded patello-femoral isolated; bi: unicompartmental plus patello-femoral; tri: tricompartmental
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with appropriateness rated as uncertain may have similar
improvements in health outcomes as patients rated as ap-
propriate. Therefore, no evidence-based indications con-
cerning THA/TKA are currently available which can be
uniformly used in daily practice.
Nonetheless, when indications were reported, the same
domains were included. Hence, although evidence based
studies are lacking, expert opinion seems reasonably
consistent. This is promising as these domains may give
clues to the targets on which future research for THA/
TKA indications should focus. It seems evident that
pain, function, radiological changes and failed conserva-
tive therapy should be part of future studies on THA/
TKA indications. The research of indication criteria is,
however, difficult. One of the difficulties is that pain and
function are relatively subjective measures both when re-
ported by the patient and when judged by the physician.
This is illustrated by the fact that although consensus on
the indication domains seems to exist, disease severity
greatly varies at the time of surgery across different cen-
tres in Europe and Australia [6, 7]. This suggests no
agreement on the cut-off values or ranges within these
domains or between combinations of domains as an in-
dication for surgery. Another difficulty is that it is not
possible to conduct controlled trials with the timing of
surgery randomized, so that other designs are needed.
As a consequence the highest level of evidence is not
likely to be obtained, but likely to be relatively low given
mainly observational studies (level II and III). However,
outcomes of observational studies can be valid and may
provide similar results as RCTs. For instance, meta-
analyses comparing RCTs and observational studies of
treatment effects found no large systematic differences
[39]. Furthermore, randomization will avoid confound-
ing by indication but this can also be achieved with ad-
vanced statistical analyses and pseudo-randomization
in observational studies. To obtain the best possible
evidence, we should try to identify predictors for a
(less than) good outcome after THA/TKA. With the
identified predictors we might be able to simulate with
mathematical modelling at which cut-off points sur-
gery has the best postoperative outcomes, taking into
account the limited lifespan of a prosthesis and the fact
that revision surgery mostly has worse outcomes than
primary surgery.
Conclusions
In conclusion, our current study gives an overview of
the available evidence base of THA/TKA indication
criteria in both guidelines and original studies. We
showed that the currently available THA/TKA indica-
tion criteria are based on limited and low quality evi-
dence. Hence, empirical research on this topic is
needed, especially regarding domain specific cut-off
values or ranges at which the best postoperative out-
comes are achieved.
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